Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer-Reference-Cited by-同舟云学术

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer

Published:2011-11 Issue:5 Volume:142 Page:1161-1167
ISSN:0022-5223
Container-title:The Journal of Thoracic and Cardiovascular Surgery
language:en
Short-container-title:The Journal of Thoracic and Cardiovascular Surgery

Author:

Alifano Marco,Falcoz Pierre E.,Seegers Valérie,Roche Nicolas,Schussler Olivier,Younes Mohamad,Antonacci Filippo,Forgez Patricia,Dechartres Agnes,Massard Gilbert,Damotte Diane,Régnard Jean-François

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference21 articles.

1. Systemic inflammation, nutritional status and survival in patients with cancer;McMillan;Curr Opin Clin Nutr Metab Care,2009

2. Cancer and inflammation: implications for pharmacology and therapeutics;Balkwill;Clin Pharmacol Ther,2010

3. Chemokines and chemokine receptors: new insights into cancer-related inflammation;Lazennec;Trends Mol Med,2010

4. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer;Allin;J Clin Oncol,2009

5. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition);Alberg;Chest,2007

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using the combined C-reactive protein and controlling nutritional status index for elderly non-small cell lung cancer;Journal of Thoracic Disease;2024-07

2. The advanced lung cancer inflammation index (ALI) predicted the postoperative survival rate of patients with non-small cell lung cancer and the construction of a nomogram model;World Journal of Surgical Oncology;2024-06-14

3. Risk factors and prognostic significance of early postoperative complications for patients who underwent pneumonectomy for lung cancer;Journal of Cardiothoracic Surgery;2024-05-03

4. Efficacy of cross‐line anti‐programmed death 1/programmed cell death‐ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study;Health Science Reports;2024-05

5. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy;Biomedicines;2024-03-19